Triglyceride-lowering therapies only provide cardiovascular clinical benefit if they also reduce apolipoprotein B levels.
TG-lowering treatments and atherosclerotic CV disease risk. A TG-lowering approach that results in TG lowering with no effect on apoB levels provides no clinical benefit; indeed, CV risk reduction is achievable when TG-lowering is accompanied by a reduction in apoB levels. TG: triglyceride; CE: cholesteryl ester; apoB: apolipoprotein B; CV: cardiovascular.
No takes yet. Share an insight, caveat, or question.
Tokgözoğlu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: